Immunotherapy advances for type 1 narcolepsy
ZHANG Hui-min
ZHAN Shu-qin
Abstract：Narcolepsy,a rare sleep disorder,is divided into type 1 and type 2,with type 1 distinguished by the significant loss of hypocretin-secreting neurons in the hypothalamus.Significant advancements have been made in the past two decades in understanding the autoimmune mechanisms and genetic predispositions of narcolepsy,particularly its strong linkage with HLA-DQB1*06:02 and other non-HLA immune genes.Present treatment modalities focus primarily on symptom manag-ement,whilst trials in immunotherapy are emergently being explored aiming to modulate immune responses and diminish attacks on hypocretin-producing neurons,thereby addressing the etiology of the condition.Treatment avenues such as intravenous immunoglobulin,corticosteroids,and monoclonal antibodies have demonstrated potential therapeutic promise;however,most are derived from case reports,and their long-term efficacy remains to be further investigated in comprehensive studies.
Keywords：type 1 narcolepsyhypocretinimmunotherapy
Publication Date：2024-10-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：7( 810-816 )